Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month Read more about Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio Read more about Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA Read more about Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
Supernus to Participate in Upcoming September Investor Conferences Read more about Supernus to Participate in Upcoming September Investor Conferences
Supernus Announces Second Quarter 2021 Financial Results Read more about Supernus Announces Second Quarter 2021 Financial Results
Supernus to Host Second Quarter 2021 Financial Results Conference Call Read more about Supernus to Host Second Quarter 2021 Financial Results Conference Call
Supernus to Present at Jefferies Virtual Healthcare Conference Read more about Supernus to Present at Jefferies Virtual Healthcare Conference
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age Read more about Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
Supernus Announces First Quarter 2021 Financial Results Read more about Supernus Announces First Quarter 2021 Financial Results
Supernus Announces Paragraph IV ANDA Filing for XADAGO® Read more about Supernus Announces Paragraph IV ANDA Filing for XADAGO®